Jasper Therapeutics Inc. Warrant (JSPRW)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Jasper Therapeutics Inc. Warrant Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| BO Brian Oliveira Clear Street Group Inc. | 100 | $8.33 | $1 | -$7.33 | -88% |
Jasper Therapeutics Inc. Warrant (JSPRW) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Jasper Therapeutics Inc. Warrant ever had a stock split?
Jasper Therapeutics Inc. Warrant Profile
| Biotechnology Industry | Healthcare Sector | Jeetinder Singh Mahal CEO | NASDAQ (CM) Exchange | 471871111 CUSIP |
| US Country | 64 Employees | - Last Dividend | - Last Split | 10 Jan 2020 IPO Date |
Overview
Jasper Therapeutics, Inc. is a clinical-stage biotechnology firm engaged in developing a range of therapeutic agents particularly focused on hematopoietic stem cell transplantation (HSCT) and gene therapies. The company is poised at the forefront of advancing treatment options for various diseases by enhancing the efficacy and safety of stem cell transplantations and gene therapy procedures. Situated in Redwood City, California, Jasper Therapeutics is pioneering in the exploration of innovative therapies with its lead product candidate, briquilimab, aiming to improve the outcomes for patients undergoing allogeneic stem cell therapy or stem cell gene therapy.
Products and Services
Jasper Therapeutics, Inc. is dedicated to developing and commercializing various therapeutic solutions across a spectrum of applications. Below is a detailed exploration of their leading offerings:
-
Briquilimab:
This is the company's flagship product, currently in clinical development. As a novel therapeutic antibody, briquilimab is designed to clear hematopoietic stem cells from the bone marrow. This process is critical for patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. The mechanism of action of briquilimab targets the selective clearance of these cells to facilitate an improved engraftment process during transplantation.
-
Conditioning Regimens for Stem Cell Transplantation:
Jasper Therapeutics is working on developing conditioning regimens that are integral to the stem cell transplantation process. These regimens are aimed at preparing the patient's body to receive the stem cells, by creating an environment conducive for the new cells. This includes the development of less toxic conditioning regimens to reduce the risks and side effects associated with transplantation procedures.
-
Stem Cell Transplants for Rare Diseases:
The company is also actively developing stem cell transplantation solutions tailored for rare diseases such as sickle cell disease, Fanconi anemia, chronic granulomatous diseases, GATA2 MDS, and severe combined immunodeficiency. These efforts reflect Jasper Therapeutics' commitment to addressing the unmet medical needs of patients with rare and challenging conditions, leveraging stem cell technology for innovative treatments.
